EnhancedBio Overview
- Year Founded
-
2016

- Status
-
Acquired/Merged
- Employees
-
12

- Latest Deal Type
-
M&A
EnhancedBio General Information
Description
Developer of anti-cancer therapeutics designed to introduce new drug forms for cancer treatment. The company's therapeutics focus on target-specific drugs and companion diagnostics for treating various cancers, enabling healthcare professionals to provide patients with the medicines to get improved cancer treatment.
Contact Information
Website
www.enhancedbio.com(Operating Subsidiary)
Corporate Office
- Room 708-711, 7th Floor, KM Tower
- 95, Gasan digital 2-ro
- Seoul, Geumcheon 08505
- South Korea
Corporate Office
- Room 708-711, 7th Floor, KM Tower
- 95, Gasan digital 2-ro
- Seoul, Geumcheon 08505
- South Korea
EnhancedBio Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Merger/Acquisition | 27-Sep-2023 | Completed | Generating Revenue | |||
4. Later Stage VC (Series C) | 20-Aug-2022 | Completed | Clinical Trials - General | |||
3. Early Stage VC | 01-Jan-2020 | Completed | Clinical Trials - General | |||
2. Early Stage VC | 31-Dec-2019 | $3.43M | $9.9M | Completed | Clinical Trials - General | |
1. Early Stage VC (Series A) | 22-Feb-2019 | $6.5M | $6.5M | Completed | Pre-Clinical Trials |
EnhancedBio Patents
EnhancedBio Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220348595-A1 | Compounds and methods for the targeted degradation of estrogen receptors | Inactive | 09-Apr-2021 | ||
EP-4268808-A1 | Lipid nanoparticles comprising mannose or uses thereof | Pending | 24-Dec-2020 | ||
JP-2024500515-A | Composition for preventing or treating cancer containing lipid nanoparticles | Pending | 24-Dec-2020 | ||
JP-2024500516-A | Lipid nanoparticles containing mannose or their uses | Pending | 24-Dec-2020 | ||
CA-3205397-A1 | Composition for preventing or treating cancer, containing lipid nanoparticles | Pending | 24-Dec-2020 | A61K45/06 |
EnhancedBio Signals
EnhancedBio Former Investors (21)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
CKD Venture Capital | Corporate Venture Capital | Minority | ||
Dongyu Technology Electronic | Corporation | Minority | ||
Friend Investment Partners (Seoul) | Venture Capital | Minority | ||
HB Investment | Venture Capital | Minority | ||
Heungkuk Securities | Corporation | Minority |
EnhancedBio FAQs
-
When was EnhancedBio founded?
EnhancedBio was founded in 2016.
-
Where is EnhancedBio headquartered?
EnhancedBio is headquartered in Seoul, South Korea.
-
What is the size of EnhancedBio?
EnhancedBio has 12 total employees.
-
What industry is EnhancedBio in?
EnhancedBio’s primary industry is Drug Discovery.
-
Is EnhancedBio a private or public company?
EnhancedBio is a Private company.
-
What is EnhancedBio’s current revenue?
The current revenue for EnhancedBio is
. -
How much funding has EnhancedBio raised over time?
EnhancedBio has raised $35.6M.
-
Who are EnhancedBio’s investors?
CKD Venture Capital, Dongyu Technology Electronic, Friend Investment Partners (Seoul), HB Investment, and Heungkuk Securities are 5 of 21 investors who have invested in EnhancedBio.
-
When was EnhancedBio acquired?
EnhancedBio was acquired on 27-Sep-2023.
-
Who acquired EnhancedBio?
EnhancedBio was acquired by TS Trillion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »